Straumann accounts for almost half of the global premium market and around 15% of the value market. Strategic tuck-in acquisitions add value in its growing portfolio and expand presence in high-growth emerging markets. The company expects positive growth in China for 2026, supported by being the only international premium brand with local manufacturing and all necessary licenses.
Cyborg Score Rationale
Straumann holds over one third of the CHF 6 billion global market with strong brand positioning. In 2024, revenue increased 9.98% to CHF 2.50 billion with earnings rising 57.81%. However, the value dental implant segment could continue to outpace the premium segment and lead Straumann to lose its foothold in the implant market.
Top Insights
Market leader with over one-third of global market and almost half of premium segment
Strong 2024 financial growth with 10% revenue increase and 58% earnings growth
Diversified brand portfolio including Straumann, Neodent, Anthogyr, and Medentika for premium and value segments
Strategic expansion focus on China and Asia-Pacific markets with significant growth potential through 2026
Named Competitors
Zimmer Biomet — Global orthopedic and dental implant systems
Astra Tech — Dental implant and prosthetic solutions
Nobel Biocare — Premium dental implant systems
Recent Developments
(February 2026) Market cap at CHF 15.71B with next earnings report Feb 18, 2026
(January 2026) 52-week trading range CHF 83.10-134.45; analyst consensus rating Buy with 11.36% upside
(2024) Record earnings growth of 57.81% on CHF 2.50B revenue base
Open the full interactive Straumann Holding AG report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.